At Retina Specialty Institute, we are recognized nationally for our participation in clinical trials and for giving our patients access to the most advanced care. We choose this path of innovation not because it is easy, but because we hold steadfastly to a vision of treating and of, someday, curing patients.
The field of retina has evolved tenfold over the past decade. This progress only fuels our desire to do more, to forge ahead, and to break out on behalf of our patients.
As a national, randomized, FDA approved clinical trial study center, Retina Specialty Institute has earned its reputation among major pharmaceutical companies, peers, and patients by delivering peak performance time and time again.
Clinical trials are conducted in a series of steps, called phases – each phase is designed to answer a separate research question.
- Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
- Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
- Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
- Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug’s effect in various populations and any side effects associated with long-term use.
Our deep and vast experience, staff certification, high-level instrumentation, ability to recruit and retain patients, proven record of capturing data effectively, and our diligence are at the core of success in a competitive, carefully screened research field.
Retina Specialty Institute has participated in clinical trials for Age-Related Wet & Dry Macular Degeneration (Wet AMD/Dry AMD), Diabetic Retinopathy/Diabetic Macular Edema, Retinal Vein Occlusion (BRVO/CRVO), and Vitromacular Traction Syndrome (VMT), which are all leading causes of blindness. Our goal is, through research, to provide patients with better results while being less intrusive.
Retina Specialty Institute is proud to be among the top national sites for clinical trials. Our commitment to research is continuously strengthened as we recognize the increased benefits for our patients. While not every patient is a candidate, everyone benefits from what we learn. The more we know, the closer we come to realizing our vision of curing all.
To learn more about clinical trials, please visit http://www.clinicaltrials.gov.